Name
Biochemotherapy
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for Biochemotherapy
Name
Alternate Names
Deticene
Detimedac
Dimethyl-triazeno-imidazole-carboxamide
DTIC-Dome
Fauldetic
Imidazole carboxamide
WR-139007
Abbreviations
DIC
DTIC
ICDT
ICT
Category
Chemotherapy
Subcategory
Antimetabolite
Nonclassic alkylating agent
NSC Number
45388
045388
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum
Abbreviations
CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
119875
Primary Site
Histology
None
Remarks
An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.
Coding
This drug should be coded
Name
Alternate Names
None
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
Other cancer
Histology
None
Remarks
Phase I Th1 cytokine. Nastech Pharmaceuticals.
Coding
This drug should be coded
Name
Alternate Names
Aldesleukin
BG-8301
Costimulator
Epidermal thymocyte activating factor
Human Jurkat Tumor Derived (Dupont)
IL-2 /Adherent LAK (CT)
IL-2 Jurkat derived
Lymphocyte mitogenic factor
Proleukin
Ril-2
T-Cell Growth Factor
Teceleukin
Thymocyte Stimulating Factor
Abbreviations
ETAF
IL-2
Ril-2
TCGF
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
364831
Primary Site
Histology
None
Remarks
Phase I (head & neck) Phase III (AML, NHL) Cytokine; Lymphokine; results in proliferation and expansion of activated T-lymphocytes
Coding
This drug should be coded
Name
Alternate Names
29060-LE
Alkaban
LE-29060
Velban
Velbe
Velsar
Vinblastine
Vinblastine sulfate
Abbreviations
VBL
VELB
VLB
Category
Chemotherapy
Subcategory
Plant alkaloid
NSC Number
049842
49842
Primary Site
None
Histology
None
Remarks
A cell cycle specific chemotherapeutic agent; vinca plant alkaloid; mitotic inhibitor. FDA approved uses in 3rd line breast cancer, choriocarcinoma, palliative in stages III and IV Hodgkin's lymphoma, Kaposi's sarcoma, mycosis fungoides, palliative in non-Hodgkin's histiocytic/lymphocytic lymphoma, and advanced testicular carcinoma.
Coding
This drug should be coded